Cerebricon Ltd. and Neuromolecular Models Inc. (Danvers, MA) Announce Strategic Alliance
30 August 2007
Cerebricon and Neuromolecular Models today have announced that they have formed a strategic alliance that will see the two companies expand their relationship to encompass projects related to Cerebricon's innovative Preclinical CNS disease modelling platforms.
The companies will also work together to support the development, testing and marketing of both established as well as new and innovative models related to Cerebricon's CNS Modelling Platforms.
This is an affirmative move to further establish and cement Cerebricon as a leader in the Preclinical testing of compounds and therapies aimed at CNS diseases and to allow it to enhance its US operations.
Cerebricon will use Neuromolecular Models' and their personnel to enhance the scientific input within its various CNS disease modelling platforms, to communicate seamlessly with clientele in North America.
Cerebricon's CEO Dr Juha Yrjänheikki speaking after the conclusion of discussions with Keith Baker of Neuromolecular Models stated, "We are pleased that we can collaborate with Neuromolecular Models in this fashion. Cerebricon is a fairly well known name within the European pharmaceutical community and with this relationship we can enhance both the quality of our service as well as increase the confidence in our service by our North American clientele. In addition, by bringing Keith Baker of Neuromolecular Models on board we gain additional insight into the needs of the North American pharmaceutical community in terms of the direction CNS drug development and CNS drug discovery is going."
